Is there a Bearish outlook for Verona Pharma plc (LON:VRP) this week?

June 19, 2018 - By Richard Conner

Verona Pharma plc (LON:VRP) Logo

Verona Pharma plc (LON:VRP) Ratings Coverage

Among 3 analysts covering Verona Pharma PLC (LON:VRP), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Verona Pharma PLC has GBX 348 highest and GBX 160 lowest target. GBX 252.67’s average target is 63.60% above currents GBX 154.44 stock price. Verona Pharma PLC had 5 analyst reports since March 2, 2018 according to SRatingsIntel. The stock has “Buy” rating by Jefferies on Friday, April 6. N+1 Singer maintained the stock with “Strong Buy” rating in Wednesday, March 21 report. As per Friday, March 2, the company rating was maintained by N+1 Singer. The stock has “Buy” rating by Shore Capital on Tuesday, May 8. Below is a list of Verona Pharma plc (LON:VRP) latest ratings and price target changes.

08/05/2018 Broker: Shore Capital Rating: Buy Old Target: GBX 173.00 New Target: GBX 160.00 Maintain
11/04/2018 Broker: Shore Capital Rating: Buy New Target: GBX 173.00 Initiates Starts
06/04/2018 Broker: Jefferies Rating: Buy Old Target: GBX 250.00 Maintain
21/03/2018 Broker: N+1 Singer Rating: Strong Buy Old Target: GBX 327.00 New Target: GBX 348.00 Maintain
02/03/2018 Broker: N+1 Singer Rating: Strong Buy Maintain

The stock decreased 0.36% or GBX 0.56 during the last trading session, reaching GBX 154.44. About 1,000 shares traded. Verona Pharma plc (LON:VRP) has 0.00% since June 19, 2017 and is . It has underperformed by 12.57% the S&P500.

Verona Pharma plc, a clinical stage biopharmaceutical company, researches, discovers, and develops therapeutic drugs to treat respiratory diseases primarily in the United Kingdom and North America. The company has market cap of 162.19 million GBP. The companyÂ’s lead product is RPL554, an inhaled dual inhibitor of the enzymes phosphodiesterase 3 and 4, which is in Phase IIa clinical trial that acts as a bronchodilator and an anti-inflammatory agent for the treatment of chronic obstructive pulmonary disease, cystic fibrosis, and asthma. It currently has negative earnings.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: